Your browser doesn't support javascript.
loading
Varicella post-exposure management for pediatric oncology patients.
Costa, Guillaume; Orbach, Daniel; Saulpic, Juliette; Sarda-Thibault, Hélène; Hanslik, Thomas; Brethon, Benoit; Tabone, Marie-Dominique; Raimbault, Sandra; Papillard, Solesne; Guillaumat, Cécile; Nathanson, Sylvie; Pellegrino, Béatrice; Belloy, Marie; Mesples, Bettina; Trioche, Pascale; Jaber, Hania; Raimondo, Graziella; Gilet, Céline; Cohen-Gogo, Sarah.
Afiliação
  • Costa G; Centre Hospitalier Sud Francilien, Corbeil-Essonnes, Department of Pediatrics, 40, Avenue Serge Dassault, 91100 Corbeil-Essonnes, France.
  • Orbach D; PSL University, SIREDO oncology center (Care, Innovation and Research for Children, Adolescents and young Adults with Cancer) Institut Curie, 26, rue d'Ulm, 75005 Paris, France.
  • Saulpic J; Centre Médical et Pédagogique Edouard Rist, Department of Hemato-Oncology, 14, Rue Boileau, 75016 Paris, France.
  • Sarda-Thibault H; Centre Hospitalier Réné Dubos, Department of Pediatrics, 6, avenue de l'Île de France, 95300 Pontoise, France.
  • Hanslik T; CHU Ambroise Paré, Department of Internal Medicine, 9, Avenue Charles de Gaulle, 92100 Boulogne-Billancourt, France.
  • Brethon B; CHU Robert-Debré, Department of Pediatric Immuno-hematology, 48, Bd Sérurier, 75019 Paris, France.
  • Tabone MD; Armand-Trousseau Sorbonne University Hospital, AP-HP, Department of Pediatric Hemato-Oncology, 26, Av. du Dr Arnold Netter, 75012 Paris, France.
  • Raimbault S; Institut Gustave Roussy, Department of Pediatric Oncology, 114, Rue Edouard Vaillant, 94805 Villejuif, France.
  • Papillard S; CHU Ambroise Paré, Department of Pediatrics, 9, Av. Charles de Gaulle, 92100 Boulogne-Billancourt, France.
  • Guillaumat C; Centre Hospitalier Sud Francilien, Corbeil-Essonnes, Department of Pediatrics, 40, Avenue Serge Dassault, 91100 Corbeil-Essonnes, France.
  • Nathanson S; Centre Hospitalier André Mignot, Department of Pediatrics, 177, Rue de Versailles, 78150 Le Chesnay-Rocquencourt, France.
  • Pellegrino B; Centre Hospitalier François Quesnay, Department of Pediatrics, 2 Bd Sully, 78200 Mantes-la-Jolie, France.
  • Belloy M; Centre Hospitalier Robert Ballanger, Department of Pediatrics, Boulevard Robert Ballanger, 93602 Aulnay-sous-Bois, France.
  • Mesples B; CHU Louis Mourier, Department of Pediatrics, 178, rue des Renouillers, 92701 Colombes, France.
  • Trioche P; CHU Antoine Béclère, Department of Pediatrics, 157, Rue de la Porte de Trivaux, 92140 Clamart, France.
  • Jaber H; Centre Hospitalier Simone Veil, Department of Pediatrics, 14, Rue de Saint-Prix, 95600 Eaubonne, France.
  • Raimondo G; Hospital Margency Croix-Rouge, Department of Pediatrics, 18, rue Roger Salengro, 95580 Margency, France.
  • Gilet C; Regional care network for pediatric hematology-oncology-Ile-de-France (RIFHOP), 3-5, rue de Metz, 75010 Paris, France.
  • Cohen-Gogo S; The Hospital for Sick Children, Division of Hematology, Oncology, Department of Pediatrics, 555, University Avenue, Toronto, Canada. Electronic address: sarah.cohen-gogo@sickkids.ca.
Bull Cancer ; 109(3): 287-295, 2022 Mar.
Article em En | MEDLINE | ID: mdl-35093244
ABSTRACT

INTRODUCTION:

The objective was to evaluate health care providers' (HCP) adherence to and efficacy of varicella post-exposure prophylaxis (PEP) recommendations. It was an observational, prospective, multicenter study set in Ile-de-France, France.

METHODS:

All children under 18 with a cancer diagnosis, currently or within 3months of receiving cancer treatment, regardless of varicella zoster virus (VZV) serostatus or previous personal history of varicella, were eligible. Study participants with significant exposure were reviewed prospectively for PEP indications. Main outcome measures were the percentage of exposure situations for which HCP were guideline-compliant, the proportion of available VZV serostatuses and the incidence of breakthrough varicella after different PEP approaches.

RESULTS:

A total of 51 patients from 15 centers were enrolled after 52 exposure episodes. Median age at exposure was 5 years (range, 1-15). Exposure within the household led to 38% of episodes. Prophylactic treatment consisted in specific anti-VZV immunoglobulins (V-ZIG) (n=19) or in oral aciclovir (n=15). No prophylactic treatment was given for 18 patients (in compliance, n=16). In compliance with guidelines, 17 patients received V-ZIG, 11 did not develop varicella (65%, [95% CI, 39-90%]); 15 received aciclovir, 13 did not develop varicella (87%, [95% CI, 67-100%]). Breakthrough varicella occurred in 11 patients, with simple clinical course in all cases; in 8/47 (17%) episodes when PEP was guideline-compliant versus 3/5 (60%) when not.

DISCUSSION:

Recommendations have been respected and are efficient. PEP needs to be standardized and a study carried out to define the optimal approach. Anti-VZV immunization of seronegative family members should be encouraged.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Varicela / Guias de Prática Clínica como Assunto / Fidelidade a Diretrizes / Profilaxia Pós-Exposição / Neoplasias Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Qualitative_research / Risk_factors_studies Limite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Varicela / Guias de Prática Clínica como Assunto / Fidelidade a Diretrizes / Profilaxia Pós-Exposição / Neoplasias Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Qualitative_research / Risk_factors_studies Limite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article